We immunoprecipitated Cdk 2 from automobile treated OV2008 cell

ctive therapeutic goal. Farletuzumab has shown great antitumoral activity in preclinicalxenograft models and has shown promising results in early phase studies. A stage 1 dose escalation study has shown no dose restricting harmful side effects or significant adverseeffects. A stage 2 efficacy and safety

show submisison details

Add To